<p>Flutamide is indicated for use in combination with LHRH agonists for the management of locally confined&nbsp;Stage&nbsp;B2-C and Stage D2&nbsp;metastatic carcinoma of the&nbsp;prostate.<br />
<br />
<strong>Stage B2-C Prostatic Carcinoma</strong>: Treatment with Flutamide and the LHRH agonist&nbsp;should start 8 weeks prior to initiating radiation therapy and continue during&nbsp;radiation&nbsp;therapy.<br />
<br />
<strong>Stage D2&nbsp;Metastatic Carcinoma</strong>: To achieve benefit from treatment, Flutamide should be initiated with the LHRH agonist and continued until progression.</p>